Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MIRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — The Chief Financial Officer departed the company effective June 6, 2026.
MIRA Pharmaceuticals CFO departs, replaced by fractional CFO at $6,000/month
Filed June 8, 2026 · Period ending June 2, 2026 · ~1 min read
Key Changes
-
high
CFO Alan Weichselbaum departed June 6, 2026; company states departure was not due to any disagreement on operations, policies, or practices.
Item 5.02 verify on EDGAR → -
high
Andriy Mushak appointed fractional CFO effective June 6, 2026, serving part-time through consulting firm LMAM rather than as full-time employee.
Item 5.02 verify on EDGAR → -
medium
New CFO will be paid $6,000 per month via consulting agreement—significantly lower than typical full-time CFO compensation for a public company.
Item 5.02 verify on EDGAR → -
medium
Mushak is a CPA with 20+ years experience in SEC reporting and accounting compliance, currently Partner at LMAM Consulting Group.
Item 5.02 verify on EDGAR →
Summary
MIRA Pharmaceuticals disclosed a CFO transition, with Alan Weichselbaum departing and being replaced by Andriy Mushak in a fractional capacity. The company emphasized Weichselbaum's departure was amicable with no disagreements.
However, the shift to a fractional CFO model—where Mushak will work part-time through his consulting firm at $6,000 monthly—represents a significant change in how the company structures its senior finance leadership. For retail investors, this raises questions about the company's financial resources and operational complexity.
A fractional CFO arrangement can work well for smaller companies with straightforward operations, but may signal cost constraints or reduced need for full-time financial oversight. Mushak brings solid credentials as a CPA with SEC reporting experience, which is critical for maintaining compliance. Watch the next 10-Q filing closely. The quality and timeliness of financial reporting under the new fractional arrangement will indicate whether this structure is adequate for MIRA's needs, or if further changes to the finance function may be necessary.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. (the “Company”). Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
Alan Weichselbaum ceased serving as Chief Financial Officer effective June 6, 2026. The company disclosed that his departure was not due to any disagreement with the company on operations, policies, or practices.
Added in current filing · verify on EDGAR →
Mr. Mushak has been, and will remain, employed by LMAM and will be providing his services pursuant to the Consulting Agreement between the Company and LMAM. The material terms of the engagement are that the Company will pay Mr. Mushak $6,000 per month for the services rendered by Mr. Mushak.
The new CFO will be compensated $6,000 per month through a consulting agreement with his firm LMAM, rather than as a direct employee. This fractional arrangement suggests a part-time or shared-services model for the CFO role.
Added in current filing · verify on EDGAR →
Mr. Mushak, CPA, 43, is an accomplished Certified Public Accountant licensed in the Commonwealth of Massachusetts with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits. Mr. Mushak currently serves as a Partner at LMAM Consulting Group, LLC (“LMAM”), a professional services firm with offices in Dallas, Texas and Boston, Massachusetts, specializing in SEC financial reporting, technical accounting, and M&A transaction support.
The new fractional CFO is a CPA with 20 years of experience in SEC reporting and accounting compliance, currently serving as a Partner at LMAM Consulting Group. His background includes leading SEC reporting engagements and serving as Senior Manager at Baker Tilly US, LLP.
Event · Item 9.01 — Financial Statements and Exhibits
MIRA Pharmaceuticals entered into a consulting agreement with LMAM Consulting Group, LLC.
Added in current filing · verify on EDGAR →
Consulting Agreement between MIRA Pharmaceuticals, Inc. and LMAM Consulting Group, LLC
The company has entered into a consulting agreement with LMAM Consulting Group, LLC. The 8-K does not provide details about the scope, duration, or financial terms of the consulting arrangement. Investors should review the attached exhibit for material terms.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify